Riskpilot← Back to searchSign inGet full accessSartar Therapeutics Oy
OYActiveY-tunnus 2754654-8Research and experimental development on natural sciences and engineering · NACE 7210Est. 20163 employeessartartherapeutics.com
Revenue 2024
EUR 0
EBITDA margin
—
+69% vs 2023
Equity ratio
-115.2%
Financial strength
Net profit 2024
EUR -396K
+68% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR -376K | +69% |
| Net profit | EUR -396K | +68% |
| Total assets | EUR 625K | -32% |
| Equity | EUR -719K | -122% |
| Employees | 3 | — |
Legal name
Sartar Therapeutics Oy
Y-tunnus number
2754654-8
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24. maaliskuuta 2016
Share capital
EUR 2 500
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on muun muassa terveystieteellinen tutkimus ja tuotekehitys. Yhtiö voi omistaa, ostaa, myydä, hallita ja vuokrata huoneistoja, kiinteistöjä, arvopapereita, osakkeita, osuuksia ja oikeuksia sekä kotimaassa että ulkomailla.
Address
Email
info@sartartherapeutics.com
Website
sartartherapeutics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | −752 | 0 |
| Staff expenses | −14 | −136 | −228 | −379 | −251 |
| EBITDA | −20 | −336 | −890 | −1 213 | −376 |
| Depreciation & amort. | −8 | −10 | −12 | −13 | −16 |
| EBIT | −28 | −347 | −901 | −1 226 | −393 |
| Net financials | −162 | −2 | −7 | 7 | −3 |
| Profit before tax | −191 | −349 | −908 | −1 219 | −396 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −191 | −349 | −908 | −1 219 | −396 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 167 | 2 170 | 1 437 | 913 | 625 |
| Equity | 2 160 | 1 812 | 896 | −323 | −719 |
| Long-term debt | — | 315 | 397 | 1 054 | 1 263 |
| Short-term debt | 6 | 43 | 144 | 182 | 81 |
| Total debt | 6 | 358 | 541 | 1 237 | 1 344 |
EBITDA margin
-37630300.0%
This company
15.8%
Market median
-238166556% vs market
20202024
Equity ratio
-115.2%
This company
38.2%
Market median
-402% vs market
20202024
Return on equity
-39592500.0%
This company
18.4%
Market median
-215176730% vs market
20202024
Net profit margin
-39592500.0%
This company
8.1%
Market median
-488796396% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.87×
This company
0.62×
Market median
-202% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MM Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (2) | ||
VP | Audit | 2018 – 2023 |
KL Chief Executive Officer | Chief Executive Officer | 2020 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2018 | |
| Chairperson | 2018 | |
| Board of Directors | 2022 | |
| Former (4) | ||
| Board of Directors | 2018 – 2022 | |
| Board of Directors | 2018 – 2022 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2018 – 2019 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sartar Therapeutics Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ville Petteri Kervinen | Audit | 0 companies |
| Mikael Maksimow | Chief Executive Officer | 0 companies |
| Katja Lotta Johanna Ivanitskiy | Chief Executive Officer | 0 companies |
| Pekka Ilmari Simula | Board of Directors | 0 companies |
| Olli-Pekka Kallioniemi | Board of Directors | 0 companies |
| Harri Jaakko Sihto | Chairperson | 0 companies |
| Jami Antero Mandelin | Board of Directors | 0 companies |
| Olli-Pekka Antero Pulkka | Board of Directors | 0 companies |
| Jyrki Pekka Sakari Mattila | Board of Directors | 0 companies |
| Heikki Tuomas Joensuu | Board of Directors | 0 companies |